Immuneering Corporation's stock is experiencing a notable rise today following the announcement of the launch of its Pancreatic Cancer Advisory Board. This development underscores the clinical progress of their lead candidate, IMM-1-104, which has recently received Orphan Drug designation and Fast Track designations for first- and second-line pancreatic cancer treatments. The establishment of this advisory board is seen as a significant step in advancing the company's efforts in addressing pancreatic cancer, a move that has likely bolstered investor confidence.
The stock opened at $1.60 and has reached a high of $1.80, currently trading at $1.79, marking a 10.51% increase from the previous close of $1.62. Despite being early in the trading day, the volume is relatively low at 220,432 shares, representing just 13.46% of the average daily volume of 1,637,404 shares.